"Designing Growth Strategies is in our DNA"

Enzymatic DNA Synthesis Market Size, Share & Industry Analysis, By Product Type (Instruments & Platforms, Reagents & Consumables, DNA Synthesis Services), By Technology (TdT-based Enzymatic Synthesis, Polymerase-based Enzymatic Synthesis, Ligation-based Synthesis), By Application (Gene & Genome Engineering, Therapeutic & Vaccine Development, Protein & Antibody Engineering, Molecular Diagnostics, Synthetic Biology), By End User (Pharmaceutical & Biotechnology Companies, Diagnostics & Genomics Companies, CROs and CDMOs, Academic & Research Institutions), and Regional Forecast, 2026-2034

Last Updated: November 02, 2026 | Format: PDF | Report ID: FBI115602

 

Enzymatic DNA Synthesis Market Size & Future Outlook

Play Audio Listen to Audio Version

The global enzymatic DNA synthesis market size was valued at USD 109.00 million in 2025. The market is projected to grow from USD 135.06 million in 2026 to USD 598.89 million by 2034, exhibiting a CAGR of 20.46% during the forecast period.

The global market is anticipated to witness substantial growth in the upcoming years. The increasing demand for rapid and accurate synthetic DNA across synthetic biology, genomics, gene editing, cell and gene therapy, and other novel biopharmaceutical research is driving this growth. Key biotechnology companies are focusing on developing enzyme-based synthesis platforms that can overcome the length, complexity, and scalability limitations associated with conventional chemical DNA synthesis. Continued advancements in enzymatic synthesis technologies are expected to improve turnaround times and enable researchers to produce increasingly complex DNA sequences. Moreover, expanding applications of synthetic DNA in advanced therapeutics, diagnostics, protein engineering, and genomic engineering are expected to propel the growth of the market during the forecast period.

  • For instance, in February 2025, DNA Script launched a new enzymatic DNA synthesis offering designed to address challenging DNA sequences, including high-GC-content regions, poly-A and poly-T sequences, inverted terminal repeats (ITRs), untranslated regions (UTRs), promoter regions, and secondary structures. The development expands the capabilities of enzymatic DNA synthesis for producing increasingly complex sequences, supporting wider adoption across advanced life science research and biopharmaceutical applications.

Major players in the market comprise Touchlight Genetics Limited, DNA Script, SAS, Elegen Corporation, and Ansa Biotechnologies, Inc. These companies are actively participating in strategic collaborations and acquisitions to expand their offerings, diversify their product portfolios, enhance market access, and strengthen their market presence.

Growing Adoption of Decentralized, Automated, and On-Demand DNA Synthesis to Emerge as a Prominent Trend

The shift toward decentralized and on-demand DNA synthesis is one of the significant market trends. Conventional DNA procurement often depends on centralized synthesis facilities and external suppliers, which can increase turnaround times and create logistical constraints for research laboratories. Enzymatic synthesis is enabling automated benchtop platforms that allow researchers to manufacture oligonucleotides directly within their laboratories. The growing adoption of these platforms can provide researchers with greater workflow control, faster design-build-test cycles, and reduced dependence on external DNA supply chains. Such continued improvements in automation, synthesis throughput, and workflow integration are expected to accelerate the adoption of decentralized DNA production.

  • For instance, in July 2026, DNA Script collaborated with Imperial Life Sciences to expand the availability of its SYNTAX enzymatic DNA synthesis platform across India. The automated benchtop platform enabled laboratories to synthesize ssDNA oligonucleotides in-house within a few hours and integrates synthesis, purification, and normalization into a single workflow.

MARKET DYNAMICS

MARKET DRIVERS

Download Free sample to learn more about this report.

Rising Demand for Long, Complex, and High-Fidelity DNA for Genetic Medicines and Genome Engineering to Drive Market Growth

The increasing demand for long, complex, and high-fidelity synthetic DNA across genetic medicines and genome engineering applications is expected to drive the global enzymatic DNA synthesis market growth. The development of gene therapies, engineered cell therapies, gene synthesis, vaccines, genome-edited organisms, and advanced biological products increasingly requires DNA constructs containing large coding sequences, regulatory elements, repetitive regions, and other difficult-to-synthesize motifs. Enzymatic DNA synthesis technologies are being developed to enable more accurate production of challenging DNA constructs while reducing extensive assembly and error-correction requirements. Furthermore, increasing research and commercial activity in gene therapy and genome engineering is expected to strengthen the demand for reliable synthesis of longer and more complex DNA, supporting market growth during the forecast period.

  • For instance, in March 2025, Syngoi Technologies collaborated with Ribbon Bio to develop and manufacture synthetic DNA for gene therapy applications. The collaboration combined Syngoi's clinical-stage synthetic DNA manufacturing capabilities with Ribbon Bio's algorithm-driven technology and precision enzymatic assembly platform to address demand for longer, higher-complexity, and high-purity synthetic DNA required for next-generation gene therapies.

Market Drivers - Impact & CAGR Contribution (2026–2034)

Rank Market Drivers Expected Impact on Market Growth Estimated Gross Market Growth Contribution (USD Million) Impact: 2026-2028 Impact: 2029-2031 Impact: 2032-2034
1 Rising demand for long, complex, and high-fidelity DNA for genetic medicines and genome engineering High 133.65 High High High
2 Cell-free/enzymatic substitution versus chemical DNA synthesis and conventional plasmid workflows High 119.33 Medium High High
3 Expansion of synthetic biology, engineered biology, and high-frequency design-build-test-learn workflows High 100.24 High High Medium
4 Growth in on-site/benchtop DNA synthesis and workflow automation Medium-High 85.92 Medium High High
5 Increasing GMP/clinical adoption of enzymatic DNA templates and therapeutic starting materials Medium 71.60 Medium Medium High
6 Others (regional commercialization, lower cost per base, broader diagnostics/genomics adoption, and data-storage R&D and licensing) Low 38.19 Low Low Low
Total Positive Growth Contribution 548.93  

Source: Fortune Business Insights

Download Free sample For In-Depth Market Restraints & Risk Analysis

MARKET RESTRAINTS

High Cost and Scale Requirements and Established DNA Production Alternatives to Restrain Market Growth

The cost and scale economics associated with enzymatic DNA synthesis are expected to restrain the growth of the global market. Conventional phosphoramidite-based DNA synthesis remains highly competitive for routine and shorter DNA sequences. At the same time, plasmid-based production and cloning workflows continue to be widely used across research and genetic medicine development. The availability, familiarity, and established economics of these incumbent methods can limit the willingness of laboratories and biopharmaceutical companies to switch to newer enzymatic platforms. Consequently, the requirement to achieve competitive manufacturing economics while displacing established workflows may restrict the broader service adoption during the forecast period.

  • For instance, in December 2025, Ansa Biotechnologies highlighted the competitive challenge facing enzymatic DNA synthesis while expanding its ultra-long clonal DNA business.

Market Restraints - Impact & Negative CAGR Contribution (2026–2034)

Rank Market Restraints Expected Impact on Market Growth Estimated Reduction in Market Size (USD Million) Impact: 2026-2028 Impact: 2029-2031 Impact: 2032-2034
1 Cost and scale economics plus strong incumbent chemical/plasmid alternatives High 36.00 High High Medium
2 Fidelity, yield, length and process-standardization constraints across emerging platforms Medium-High 24.00 High Medium Medium
3 Regulatory, biosafety, sequence-screening and validation burden Medium 16.00 Medium Medium Low
4 Others (customer qualification cycles, funding volatility, IP concentration and fragmented standards) Low 9.10 Low Low Low
Total Negative Growth Impact 85.1  

Source: Fortune Business Insights

Download Free sample For In-Depth Market Restraints & Risk Analysis

MARKET OPPORTUNITIES

Expansion of GMP-Compatible and Therapeutic-Grade DNA Starting Materials to Create Lucrative Growth Opportunities

The expansion of enzymatic DNA synthesis from primarily research-grade applications toward GMP-compatible and therapeutic-grade DNA starting materials is expected to create significant growth opportunities for market players. The increasing development of mRNA therapeutics, personalized vaccines, gene therapies, engineered cell therapies, and other nucleic acid-based medicines is generating the demand for DNA templates with high purity, sequence accuracy, consistency, and traceability. As enzymatic synthesis platforms advance in scalability, quality systems, analytical validation, and GMP compatibility, manufacturers could extend their offerings from discovery and preclinical research into clinical development and commercial biomanufacturing workflows. This transition would substantially increase the addressable market and enable enzymatic DNA synthesis providers to capture higher-value applications across the genetic medicines industry.  

  • For instance, in February 2025, DNA Script and EVA Pharma collaborated with Quantoom Biosciences to develop a biologics platform for mRNA and self-amplifying RNA vaccines and therapeutics in Egypt. The collaboration demonstrates the increasing potential to integrate enzymatic DNA synthesis directly into regulated therapeutic manufacturing workflows rather than limiting the technology to research applications.

MARKET CHALLENGES

Limited Commercial Scale Validation of Enzymatic DNA Synthesis Technologies May Hinder Wider Adoption

The limited commercial scale validation of DNA synthesis technologies remains an important challenge for the global market. Although enzymatic platforms have demonstrated advantages in speed, sequence complexity, decentralization, and reduced use of hazardous chemicals, several technologies are still progressing from laboratory and research-scale applications toward high-throughput and large-scale DNA manufacturing. Scaling these platforms requires consistent synthesis yield, sequence fidelity, reproducibility, purification efficiency, and cost performance across substantially larger production volumes. Moreover, pharmaceutical and biotechnology companies require robust validation before integrating new DNA synthesis technologies into critical therapeutic development and manufacturing workflows. The requirement for additional scale-up studies, process optimization, and real-world commercial validation may, therefore, lengthen adoption cycles and restrict the near-term penetration of enzymatic approaches compared to established DNA manufacturing technologies.

Segmentation Analysis

By Product Type

DNA Synthesis Services Segment Led the Market due to Growing Preference for Outsourced Access to Advanced DNA Synthesis Capabilities

Based on product type, the market is categorized into instruments & platforms, reagents & consumables, DNA synthesis services, and software & other solutions.

The DNA synthesis services segment dominated the market in 2025. Pharmaceutical, biotechnology, and academic organizations increasingly require customized DNA without making substantial investments in specialized synthesis instruments and quality control infrastructure. The enzymatic synthesis of long and complex constructs requires considerable technical expertise and outsourcing allows researchers to obtain sequence-verified and application-ready DNA while reducing internal workflow complexity. Consequently, the combination of lower upfront requirements, access to specialized capabilities, and increasing demand for customized DNA supported the higher adoption of DNA synthesis services.

  • For instance, in May 2024, Ansa Biotechnologies expanded its early access program for complex DNA synthesis services, allowing a larger number of customers globally to access its enzymatic DNA synthesis technology for healthcare and life-science research applications. The expansion reflected the increasing customer preference for accessing advanced enzymatic synthesis capabilities through specialized service providers rather than developing such capabilities internally.

The software & other solutions segment is expected to grow at a CAGR of 21.93% over the forecast period.

To know how our report can help streamline your business, Speak to Analyst

By Technology

Higher Commercial Maturity and Efficient Template-Free DNA Extension Supported TdT-Based Enzymatic Synthesis Segment Dominance

Based on technology, the market is segmented into TdT-based enzymatic synthesis, polymerase-based enzymatic synthesis, ligation-based enzymatic synthesis, and other enzymatic synthesis technologies.

In 2025, the TdT-based enzymatic synthesis segment captured the largest market share. The segment dominance is due to the suitability of terminal deoxynucleotidyl transferase for template-free DNA synthesis, which enables controlled synthesis of user-defined DNA sequences without requiring an existing DNA template. Moreover, TdT-based approaches have progressed further toward commercial benchtop platforms, integrated reagent systems, and automated workflows compared to several alternative enzymatic synthesis approaches. The presence of commercially available platforms using this mechanism has, therefore, increased technology awareness and practical utilization, supporting the segment's dominant position.

  • For instance, in June 2021, DNA Script launched the SYNTAX System, the first benchtop nucleic acid printer powered by its enzymatic DNA synthesis The automated system enabled parallel production of 96 DNA oligonucleotides. It established one of the earliest commercially deployed platforms based on the company's engineered-enzyme synthesis approach, strengthening the commercial position of TdT-based enzymatic synthesis.

The polymerase-based enzymatic synthesis segment is projected to grow at a CAGR of 22.39% during the forecast period.

By DNA Output Type

Linear Single-Stranded DNA Segment Led the Market due to Broad Utilization across CRISPR-related Workflows and Assay Development

Based on DNA output type, the market is segmented into linear single-stranded DNA, linear double-stranded DNA, circular single-stranded DNA, circular double-stranded DNA, and others.

In 2025, the linear single-stranded DNA segment accounted for the largest enzymatic DNA synthesis market share. The dominance of the segment is due to its extensive utilization as a fundamental input across PCR, sequencing, gene assembly, mutagenesis, CRISPR-related workflows, assay development, and synthetic biology research. The comparatively straightforward production workflow and the large recurring requirement for customized oligonucleotides across research laboratories increases both synthesis volume and frequency of use. Consequently, broad application diversity and direct compatibility with enzymatic synthesis platforms supported the dominance of the segment.

  • For instance, in March 2026, DNA Script partnered with Gencell, Bio-Medical Science, and Biostream to expand its SYNTAX platform across Latin America, South Korea, and Japan. The company specifically highlighted the increasing global access to high-quality ssDNA oligonucleotides produced within hours using its automated enzymatic synthesis platform, demonstrating the broad commercial demand for linear ssDNA outputs.

The circular double-stranded DNA segment is projected to grow at a CAGR of 22.67% during the forecast period.

By Application

Increasing Requirement for Customized DNA Constructs in Genome Modification Supported the Dominance of Gene & Genome Engineering

Based on application, the market is segmented into gene & genome engineering, therapeutic & vaccine development, protein & antibody engineering, molecular diagnostics, genomics & sequencing, synthetic biology, DNA data storage, and others.

The gene & genome engineering accounted for the largest market share in 2025. Genome-editing and synthetic-biology workflows require a continuous supply of customized DNA for CRISPR experiments, gene assembly, genomic integration, pathway engineering, transgenic model generation, and large-scale genome redesign. Enzymatic DNA synthesis expands the accessible sequence design space and can shorten the time between DNA design and experimental testing. As a result, the increasing adoption of genome editing and iterative design-build-test workflows directly increases the demand for rapid and high-fidelity synthetic DNA, supporting the segment's dominant position.

  • For instance, in April 2026, Ansa Biotechnologies announced that its sequence-perfect clonal DNA products ranging from 100 bp to 50 kb were being used to enable applications including next-generation cell & gene therapies and genome engineering. The availability of substantially longer and more complex constructs allows researchers to undertake genome-engineering designs that are difficult to execute using conventional short-fragment synthesis workflows.

The DNA data storage segment is projected to grow at a CAGR of 26.03% during the forecast period.

By End User

Pharmaceutical & Biotechnology Companies Segment Led the Market due to Expanding Consumption across Cell & Gene Therapy Development

Based on end user, the market is segmented into pharmaceutical & biotechnology companies, diagnostics & genomics companies, CROs & CDMOs, academic & research institutions, and others.

The pharmaceutical & biotechnology companies segment dominated the market in 2025 owing to the substantial consumption of custom DNA across drug discovery, cell & gene therapy development, vaccine research, antibody engineering, protein optimization, synthetic biology, and nucleic acid therapeutics. These companies conduct large numbers of iterative experiments and require DNA with high sequence accuracy, reproducibility, and increasingly greater length and complexity. Furthermore, the growing pipeline of genetic medicines is increasing the requirement for synthetic DNA from early discovery through preclinical development and therapeutic manufacturing workflows. Higher R&D expenditure and the ability of biopharmaceutical companies to adopt premium, advanced synthesis technologies consequently generate greater commercial demand compared to other segments.

  • For instance, in May 2025, Ribbon Bio launched MiroSynth DNA, its first commercial synthetic DNA offering, specifically targeting advanced applications in biopharma, life sciences, and academic research. The product provides long and highly accurate synthetic DNA using algorithm-driven technology and precision enzymatic assembly, highlighting increasing commercial demand from biopharmaceutical organizations for complex DNA required in next-generation therapeutic development.

The CROs & CDMOs segment is projected to grow at a CAGR of 22.65% over the forecast period.

Enzymatic DNA Synthesis Market Regional Outlook

By geography, the market is categorized into Europe, North America, Asia Pacific, Latin America, and the Middle East & Africa.

North America

North America Enzymatic DNA Synthesis Market Size, 2025 (USD Million)

To get more information on the regional analysis of this market, Download Free sample

North America was valued at USD 36.32 million in 2024 and accounted for a leading position with a value of USD 48.60 million in 2025. The market is growing in North America due to the strong presence of synthetic biology, genomics, gene therapy, and biotechnology companies that require rapid access to customized DNA. High R&D spending and early adoption of automated and benchtop DNA synthesis platforms further support regional demand.

U.S. Enzymatic DNA Synthesis Market

Given North America's substantial contribution and the U.S. dominance in the region, the U.S. market is estimated to reach around USD 55.36 million in 2026, accounting for roughly 40.99% of the global market.

Europe

The Europe market is projected to grow at a CAGR of 19.17% over the forecast period. The region is anticipated to reach a valuation of USD 36.52 million by 2026, becoming the second-largest market by region. The Europe market growth is supported by expanding research in synthetic biology, advanced therapeutics, and genome engineering across major biotechnology hubs in the U.K., Germany, France, and other European countries. Increasing investments in localized biomanufacturing and nucleic acid-based therapeutics are also creating demand for advanced DNA synthesis technologies.

U.K. Enzymatic DNA Synthesis Market

The U.K. market is estimated to reach USD 8.09 million in 2026, accounting for roughly 5.99% of the global market.

Germany Enzymatic DNA Synthesis Market

The Germany market is projected to reach approximately USD 8.74 million in 2026, equivalent to around 6.47% of the global market.

Asia Pacific

The Asia Pacific market is estimated to reach USD 31.54 million in 2026 and secure the third-largest position in the market. The market is expanding rapidly due to growing investments in domestic life-science infrastructure and demand for faster, locally available DNA synthesis services

Japan Enzymatic DNA Synthesis Market

The Japan market is estimated to touch around USD 7.57 million in 2026, accounting for approximately 5.61% of the global market.

China Enzymatic DNA Synthesis Market

The China market is projected to be among the largest markets worldwide, with 2026 revenues estimated to reach USD 9.45 million, accounting for approximately 7.00% of global sales.

India Enzymatic DNA Synthesis Market

The India market is estimated to touch around USD 3.22 million in 2026, accounting for roughly 2.39% of global revenue.

Latin America and the Middle East & Africa

Latin America is expected to witness moderate growth during the forecast period. The market in Latin America is estimated to reach a valuation of USD 4.46 million in 2026. The regional market growth is being supported by the gradual expansion of molecular biology, genomics, and biotechnology research across Brazil, Mexico, Argentina, and other regional markets. In the Middle East & Africa, the GCC is set to reach USD 1.37 million in 2026.

South Africa Enzymatic DNA Synthesis Market

The South Africa market is projected to reach approximately USD 0.09 million by 2026, accounting for roughly 0.66% of global revenue.

COMPETITIVE LANDSCAPE

Key Industry Players

Leading Companies Emphasize Sequence Fidelity and DNA Length to Consolidate their Industry Foothold

The global enzymatic DNA synthesis market is characterized by innovation-driven competition among specialized synthetic DNA companies and established life-science technology providers. DNA Script SAS, Ansa Biotechnologies, Inc., Touchlight Genetics Limited, Elegen Corporation, and 4basebio PLC maintain prominent positions through differentiated enzymatic and cell-free DNA synthesis technologies. These companies are focusing on improving DNA length, sequence fidelity, synthesis speed, difficult-sequence capability, automation, scalability, and therapeutic-grade manufacturing. Therefore, technological performance, ability to synthesize increasingly complex DNA constructs, turnaround time, and expansion into genetic medicine applications are becoming major areas of competitive differentiation.

  • For instance, in March 2026, Touchlight Genetics Limited and New England Biolabs, Inc. launched the EnClose Cell-free dbDNA Synthesis Kit, a benchtop solution enabling rapid enzymatic production of Touchlight's doggybone DNA. The launch expanded access to cell-free DNA production directly within research laboratories. It strengthened the companies' positioning in DNA and RNA therapeutic development by providing an alternative to conventional plasmid-based manufacturing.

Other companies are strengthening their positions through specialized synthesis platforms, long and complex DNA capabilities, decentralized production, enzyme engineering, and therapeutic-grade DNA manufacturing. Companies such as Telesis Bio Inc., Camena Bioscience Limited, Ribbon Bio GmbH, and Moligo Technologies AB participate across different areas of the enzymatic DNA synthesis ecosystem. Consequently, factors such as synthesis accuracy, construct length and complexity, scalability, pricing, automation, GMP compatibility, strategic collaborations, and geographical expansion are expected to contribute to these companies’ market presence.

LIST OF KEY ENZYMATIC DNA SYNTHESIS COMPANIES PROFILED

  • Touchlight Genetics Limited (U.K.)
  • DNA Script, SAS (France)
  • Elegen Corporation (U.S.)
  • Ansa Biotechnologies, Inc. (U.S.)
  • Aldevron, LLC (U.S.)
  • Telesis Bio Inc. (U.S.)
  • 4basebio PLC (U.K.)
  • Camena Bioscience Limited (U.K.)
  • Ribbon Bio GmbH (Austria)
  • Moligo Technologies AB (Sweden)
  • TriLink BioTechnologies, LLC (U.S.)
  • New England Biolabs, Inc. (U.S.)
  • Codexis, Inc. (U.S.)
  • Evonetix Ltd (U.K.)
  • Kern Systems, Inc. (U.S.)

KEY INDUSTRY DEVELOPMENTS

  • August 2026: DNA Script collaborated with GE HealthCare. The collaboration focused on developing modular and automated cell-free DNA bioproduction using DNA Script's enzymatic DNA synthesis technology, thereby supporting the development of distributed DNA manufacturing for vaccines, personalized medicines, and other genetic health applications.
  • July 2026: DNA Script partnered with Imperial Life Sciences to expand access to its SYNTAX enzymatic DNA synthesis platform across India. The agreement provides researchers with local access to automated, in-house ssDNA oligonucleotide synthesis and strengthens the company's presence in India's growing biotechnology and life-sciences research ecosystem.
  • May 2026: 4basebio PLC launched its high-capacity enzymatic single-stranded DNA platform for gene-editing applications. The platform enables the production of long-form ssDNA constructs of up to 10,000 nucleotides. This is expected to support the growing demand for high-purity DNA templates for CRISPR-based gene editing and advanced genetic therapies.
  • April 2026: Touchlight partnered with SVF Vaccines to advance an innovative Hepatitis B/D vaccine into clinical development. The partnership utilized Touchlight's proprietary cell-free enzymatic doggybone DNA technology and expands the application of enzymatically manufactured DNA in next-generation vaccine development.
  • March 2026: Touchlight, in collaboration with New England Biolabs, launched the EnClose Cell-free dbDNA Synthesis Kit, a benchtop solution for the rapid enzymatic production of doggybone DNA. The launch expands access to decentralized cell-free DNA production and supports research and development of mRNA therapeutics, gene therapies, and other nucleic acid-based medicines.
  • March 2026: DNA Script announced distribution agreements with Gencell, Bio-Medical Science, and Biostream to expand access to its SYNTAX platform across Latin America, South Korea, and Japan. The development strengthens the company's global distribution network and supports the wider adoption of decentralized and on-demand enzymatic DNA synthesis.

REPORT COVERAGE

The global enzymatic DNA synthesis market report provides market size estimates and forecasts for all key segments covered in the study. The market outlook also evaluates the key drivers, restraints, opportunities, challenges, and emerging trends expected to influence market growth during the forecast period. Additionally, the report presents a comprehensive market analysis and a detailed competitive landscape covering estimated market shares, strategic collaborations, geographical presence, recent developments, and profiles of key market participants.

Request for Customization   to gain extensive market insights.

Report Scope & Segmentation

ATTRIBUTE DETAILS
Study Period 2021-2034
Base Year 2025
Estimated Year  2026
Forecast Period 2026-2034
Historical Period 2021-2024
Growth Rate CAGR of 20.46% from 2026 to 2034
Unit Value (USD Million)
Segmentation  By Product Type, Technology, DNA Output Type, Application, End User, and Region
By Product Type
  • Instruments & Platforms
  • Reagents & Consumables
  • DNA Synthesis Services
  • Software & Other Solutions
By Technology
  • TdT-based Enzymatic Synthesis
  • Polymerase-based Enzymatic Synthesis
  • Ligation-based Enzymatic Synthesis
  • Other Enzymatic Synthesis Technologies
By DNA Output Type
  • Linear Single-stranded DNA
  • Linear Double-stranded DNA
  • Circular Single-stranded DNA
  • Circular Double-stranded DNA
  • Others
By Application
  • Gene & Genome Engineering
  • Therapeutic & Vaccine Development
  • Protein & Antibody Engineering
  • Molecular Diagnostics
  • Genomics & Sequencing
  • Synthetic Biology
  • DNA Data Storage
  • Others
By  End User
  • Pharmaceutical & Biotechnology Companies
  • Diagnostics & Genomics Companies
  • CROs & CDMOs
  • Academic & Research Institutions
  • Others
By Region 
  • North America (By Product Type, Technology, DNA Output Type, Application, End User, and Country)
    • U.S. 
    • Canada
  • Europe (By Product Type, Technology, DNA Output Type, Application, End User, and Country/Sub-region)
    • Germany 
    • U.K.
    • France 
    • Spain 
    • Italy 
    • Scandinavia 
    • Rest of Europe
  • Asia Pacific (By Product Type, Technology, DNA Output Type, Application, End User, and Country/Sub-region)
    • China 
    • Japan 
    • India 
    • Australia 
    • Southeast Asia 
    • Rest of Asia Pacific 
  • Latin America (By Product Type, Technology, DNA Output Type, Application, End User, and Country/Sub-region)
    • Brazil
    • Mexico
    • Rest of Latin America
  • Middle East & Africa (By Product Type, Technology, DNA Output Type, Application, End User, and Country/Sub-region)
    • GCC
    • South Africa
    • Rest of the Middle East & Africa

Research Methodology

1. Bottom Up Approaches

Approach 1:  Company and Technology Revenue-Attribution Model

  • Collection of company-level revenues, annual reports, investor presentations, official technology disclosures, product portfolios, pricing information, customer base, installed platforms, partnerships, and geographical presence of major enzymatic DNA synthesis companies
  • Estimation of enzymatic DNA synthesis-attributable revenue from instruments & platforms, reagents & consumables, DNA synthesis services, and software & other solutions
  • The revenue attributable to enzymatic DNA synthesis was adjusted for private-company revenue proxies, commercialization stage, regional presence, capacity, customer adoption, and product availability wherever applicable
  • The summation of enzymatic DNA synthesis-attributable revenues of major market participants was used to estimate the overall market and calculate company market shares based on manufacturer/developer net sales, excluding chemical DNA/RNA synthesis, sequencing, PCR, and conventional plasmid revenues

Approach 2: Country-level DNA Synthesis Demand and R&D Spending Model

  • Collection of country-level data on pharmaceutical, biotechnology, genomics, synthetic biology, gene therapy, and academic R&D activity across major developed and emerging markets
  • Assessment of biotechnology R&D expenditure, government science funding, research-institute concentration, CRO/CDMO presence, genomics infrastructure, and number of potential enzymatic DNA synthesis users
  • Country-level demand was adjusted based on local availability of enzymatic DNA synthesis services, installed platforms, technology adoption, purchasing capacity, and maturity of the synthetic biology ecosystem.
  • Individual country estimates were aggregated into North America, Europe, Asia Pacific, Latin America, and the Middle East & Africa and cross-validated against company revenues and regional commercialization activity.

Approach 3:  Application/End-user Volume × Price Model

  • Estimation of annual enzymatic DNA synthesis consumption across gene & genome engineering, therapeutic & vaccine development, protein & antibody engineering, molecular diagnostics, genomics & sequencing, synthetic biology, and DNA data-storage applications
  • Demand was mapped across pharmaceutical & biotechnology companies, diagnostics & genomics companies, CROs & CDMOs, and academic & research institutions, along with the required DNA output types.
  • Commercial pricing was estimated using per-base, per-construct, service, reagent, consumable, and instrument pricing and adjusted for DNA length, sequence complexity, purity, synthesis scale, turnaround time, and fidelity requirements.
  • Application- and end-user-specific volumes were multiplied by realized manufacturer/service-provider prices to derive market revenue and were subsequently cross-checked against supplier revenues and commercial order volumes.

2. Top Down Approaches

Approach 1: Analysis of Parent Markets & Credible Secondary Sources

  • Analysis of related parent markets such as the DNA synthesis market and estimating the share attributed to enzymatic DNA synthesis
  • Collection and validation of market inputs using company annual reports, SEC/exchange filings, investor presentations, product catalogs, technical documents, patents, licensing agreements, manufacturing disclosures, launch announcements, and official pricing information
  • Review of institutional and public sources including NIH/NCBI, ClinicalTrials.gov, OECD, World Bank, national science funding agencies, government biotechnology programs, and peer-reviewed scientific literature
  • Secondary source evidence was used to validate technology adoption, synthetic biology activity, gene therapy and genome-editing research, DNA synthesis demand, commercialization timelines, and regional market development.
  • Third-party market research publications were excluded as primary evidence and all major assumptions derived through other estimation approaches were triangulated against credible company, institutional, and publicly available sources.

3. List of Key Sources

  • Company press releases covering product launches, partnerships, licensing, capacity expansion, distribution agreements, and commercialization
  • Product catalogs, technical datasheets, application notes, pricing information, and platform specifications
  • NIH, NCBI, NHGRI, NSF, ARPA-H, CEPI, and other public science-funding agencies.
  • S. FDA, EMA, European Commission, PMDA/MHLW, NMPA, CDSCO/DCGI, TGA, and other regulatory authorities
  • gov and other clinical-trial registries for gene therapy, genome editing, mRNA, vaccine, and nucleic-acid applications
  • USPTO, EPO, and WIPO for patents related to enzymatic DNA synthesis technologies.
  • OECD, World Bank, Eurostat, UNESCO, and national science agencies for R&D and biotechnology activity.
  • UN Comtrade, customs databases, and national trade statistics for supply-side validation.
  • Peer-reviewed journals such as Nature Biotechnology, Nature Methods, Nucleic Acids Research, and ACS Synthetic Biology

4. Primary Interviews

Supply Side Interviews: 60%

  • Key Respondents:
    • Enzymatic DNA synthesis platform and service providers
    • Synthetic DNA technology developers and company executives
    • Enzyme, reagent, and consumable suppliers
    • Business development, product, marketing, and sales professionals
    • Manufacturing, scale-up, and process-development teams
    • Regulatory, quality, and GMP manufacturing professionals
    • Distribution and channel partners
    • Technology licensing and commercialization experts

Demand Side Interviews: 40%

  • Key Respondents:
    • Pharmaceutical and biotechnology R&D professionals
    • Cell & gene therapy and mRNA development teams
    • Synthetic biology and genome-engineering researchers
    • Genomics and molecular diagnostics laboratories
    • CRO and CDMO professionals
    • Academic and research-institute scientists
    • Laboratory procurement and purchasing managers
    • DNA synthesis users and application-development specialists


Frequently Asked Questions

According to Fortune Business Insights, the global market value stood at USD 109.00 million in 2025 and is projected to reach USD 598.89 million by 2034.

In 2025, North America’s market value stood at USD 48.60 million.

The market is expected to grow at a CAGR of 20.46% over the forecast period of 2026-2034.

The DNA synthesis services segment led the market based on product type in 2025.

The rising demand for long, complex, and high-fidelity DNA for genetic medicines and genome engineering is a key factor driving market growth.

Touchlight Genetics Limited, DNA Script, SAS, Elegen Corporation, and Ansa Biotechnologies, Inc. are among the major players in the global market.

North America dominated the market in 2025.

Seeking Comprehensive Intelligence on Different Markets?Get in Touch with Our Experts Speak to an Expert
  • 2021-2034
  • 2025
  • 2021-2024
  • 190
Download Free Sample

    man icon
    Mail icon
    Mail icon
Jump to Content

Get 30-60 hrs Free Customization

Expand Regional and Country Coverage, Segments Analysis, Company Profiles, Competitive Benchmarking, and End-user Insights.

Growth Advisory Services
    How can we help you uncover new opportunities and scale faster?
Healthcare Clients
3M
Toshiba
Fresenius
Johnson
Siemens
Abbot
Allergan
American Medical Association
Becton, Dickinson and Company
Bristol-Myers Squibb Company
Henry Schein
Mckesson
Mindray
National Institutes of Health (NIH)
Nihon Kohden
Olympus
Quest Diagnostics
Sanofi
Smith & Nephew
Straumann